ArticlePediatric nephrology (Berlin, Germany)2019
Hemolytic uremic syndrome in a developing country: Consensus guidelines.
Article in Pediatric nephrology (Berlin, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 5 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- A systematic review of short-term outcomes in patients with anti-factor H associated atypical HUS managed with plasma exchanges versus eculizumab.Pediatric nephrology (Berlin, Germany) · 2026Pooled it
- Comparison between effectiveness and safety of plasma therapy and complement inhibitors for the treatment of atypical hemolytic uremic syndrome: a systematic review and meta-analysis of real-world data.Pediatric nephrology (Berlin, Germany) · 2026Pooled it
- AsPNA Clinical Practice Guidelines for the management of infection-related glomerulonephritis.Pediatric nephrology (Berlin, Germany) · 2026Guideline
- Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review.Pediatric nephrology (Berlin, Germany) · 2024Pooled it
- Recommendations for diagnosis and treatment of Atypical Hemolytic Uremic Syndrome (aHUS): an expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA-SBN).Jornal brasileiro de nefrologiaGuideline
- Atypical Hemolytic Uremic Syndrome With Hypocellular Bone Marrow: A Report of a Rare Case.Cureus · 2026Article
- Comprehensive gene profiling by Next-Generation sequencing in a cohort of Egyptian pediatric Atypical HUS.Journal, genetic engineering & biotechnology · 2026Article
- Liver Involvement in Children with Hemolytic Uremic Syndrome: Clinical Significance and Prognostic Value.Children (Basel, Switzerland) · 2025Article
- Evaluation of Hypertension in Pediatric Hemolytic Uremic Syndrome (A Cross-Sectional Study).Health science reports · 2025Article
- Navigating Pediatric Atypical Hemolytic Uremic Syndrome: A Two-Year Case Series From Eastern India.Cureus · 2025Article
- Identification of a new CD46 gene mutation site in a family with atypical hemolytic uremic syndrome.BMC nephrology · 2025Article
- Short-Term Efficacy of Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome.Indian journal of pediatrics · 2025Article
- Influenza A H1N1 Triggering Complement-Mediated Hemolytic Uremic Syndrome.Journal of medical cases · 2025Article
- Abbreviated protocol of plasma exchanges for patients with anti-factor H associated hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2024Article
- Anti-factor B antibodies in atypical hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2024Article
- A Severe Form of Atypical Hemolytic Uremic Syndrome in a Two-Year-Old Girl: A Case Report.Cureus · 2024Article
- Ultrasound analysis of different forms of hemolytic uremic syndrome in children.Frontiers in pediatrics · 2024Article
- Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP.International journal of molecular sciences · 2023Article
- Etiology and outcomes of acute kidney disease in children: a cohort study.Clinical and experimental nephrology · 2023Article
- Clinical features of children with anti-CFH autoantibody-associated hemolytic uremic syndrome: a report of 8 cases.Renal failure · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundHemolytic uremic syndrome (HUS) is a leading cause of acute kidney injury in children. Although international guidelines emphasize comprehensive evaluation and treatment with eculizumab, access to diagnostic and therapeutic facilities is limited in most developing countries. The burden of Shiga toxin-associated HUS in India is unclear; school-going children show high prevalence of anti-factor H (FH) antibodies. The aim of the consensus meeting was to formulate guidelines for the diagnosis and management of HUS in children, specific to the needs of the country.
methodsFour workgroups performed literature review and graded research studies addressing (i) investigations, biopsy, genetics, and differential diagnosis; (ii) Shiga toxin, pneumococcal, and infection-associated HUS; (iii) atypical HUS; and (iv) complement blockade. Consensus statements developed by the workgroups were discussed during a consensus meeting in March 2017.
resultsAn algorithm for classification and evaluation was developed. The management of Shiga toxin-associated HUS is supportive; prompt plasma exchanges (PEX) is the chief therapy in patients with atypical HUS. Experts recommend that patients with anti-FH-associated HUS be managed with a combination of PEX and immunosuppressive medications. Indications for eculizumab include incomplete remission with plasma therapy, life-threatening features, complications of PEX or vascular access, inherited defects in complement regulation, and recurrence of HUS in allografts. Priorities for capacity building in regional and national laboratories are highlighted.
conclusionsLimited diagnostic capabilities and lack of access to eculizumab prevent the implementation of international guidelines for HUS in most developing countries. We propose practice guidelines for India, which will perhaps be applicable to other developing countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.